To promote academic communications and stimulate academic innovation, the Academy of Medical Sciences will invite Professor Wang Wei from the R. Ken Coit School of Pharmacy at the University of Arizona to give an academic lecture to our teachers and students. We welcome all teachers and students to participate!
Lecture title: Development of Chemical Tools toStudyChemistry,Biology andMedicine
Lecture time: June 5th(Wednesday)9:00-10:30 am
Lecture location: Conference Room, 7th Floor, Postdoctoral Building, Academy of Medical Sciences, East Campus of Zhengzhou University
Brief introduction:
Wei Wang, Coit professor and Co-Director of the Arizona Center for Drug Discovery in the Department of Pharmacology and Toxicology. Professor Wang obtained hisBachelor’s degree from the Department of Chemistry at Nanjing Normal University in 1988.In 1993,he obtained a Master's degree from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. In 2000, he obtainedPh.D. from North Carolina State University in the US. From 2000 to 2001, he was a postdoctoral fellow in the Department of Chemistry at the University of Arizona in the United States. He was a senior researcher at the Novartis Institute of Genetics in the US between 2001-2003. In 2009, he was enrolled in the first batch of "Thousand Talents Program". Before joining the UA in 2018, he was a full professor in the Department of Chemistry and Chemical Biology at the University of New Mexico in Albuquerque.
Professor Wang Wei's research interests mainly include novel and practical synthetic methodologies, chemical biology, synthetic biology, and the development of new drugs. So far, he has published more than 350 papers in journals includingNature Catal.,Nature Mol. Biol.,Chem.,Nature Commun.,J. Am. Chem. Soc.,Angew. Chem., with an H-index of 85.He is an author or co-author of 12 patents, 1 monograph, and 20 chapters. He established three biotechnology companies in the US, dedicating to researching and developing new drugs in areas such as anti-cancer and neurodegenerative diseases. The chiral pyrrolidone sulfonamide catalyst has been successfully transferred to Aldrich Chemical in the United States, and the PTPRD inhibitors have been transferred to Novo Nordisk. Phase I clinical trial is currently underway, which is expected to be used for the treatment of drug addiction. He is a Fellow of the American Academy of Medicine and Biotechnology (AIMBE). He has served as thechairman of Chinese-American Chemistry & Chemical Biology Professors Association (CAPA). He is also a co-editor ofGreen Synthesis and Catalysisand a member ofActa Pharmaceutica Sinica BandChinese Chemical Letterseditorial board.
